Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: March 24, 2008
Last updated: April 21, 2015
Last verified: April 2015
The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients

Condition Intervention Phase
Drug: Risperidone
Drug: Ziprasidone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Six Week, Multicenter, Double Blind, Double-Dummy, Parallel, Comparative Study To Compare The Efficacy, Safety And Tolerability Of Ziprasidone With Risperidone In The Treatment Of Chinese Subjects With Acute Exacerbation Of Schizophrenia

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: Week 6 ]

Secondary Outcome Measures:
  • Adverse events, laboratory test changes, movement disorder scale scores [ Time Frame: Weeks 1, 2, 4, and 6 ]
  • Change from baseline in PANSS negative subscale score [ Time Frame: Weeks 1, 2, 4, and 6 ]
  • Change from baseline in PANSS general psychopathology subscale score [ Time Frame: Weeks 1, 2, 4, and 6 ]
  • PANSS responder rate [ Time Frame: Weeks 1, 2, 4 and 6 ]
  • Clinical Global Impression-Severity (CGI-S) score [ Time Frame: Baseline and Weeks 1, 2, 4, and 6 ]
  • Change from baseline in Brief Psychiatric Rating Scale derived (BPRSd) score [ Time Frame: Weeks 1, 2, 4, and 6 ]
  • Change from baseline in PANSS positive subscale score [ Time Frame: Weeks 1, 2, 4, and 6 ]
  • Clinical Global Impression-Improement (CGI-I) score [ Time Frame: Weeks 1, 2, 4, and 6 ]

Enrollment: 242
Study Start Date: July 2004
Study Completion Date: May 2005
Arms Assigned Interventions
Active Comparator: A Drug: Risperidone
Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
Experimental: B Drug: Ziprasidone
Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hospitalized patients with schizophrenia
  • Miminum PANSS score of 60 when randomized

Exclusion Criteria:

  • Planned, regular use of antipsyhotics within 1 week of randomization
  • Previous treatment with risperidone that resulted in intolerance or lack of response to risperidone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00645372

Pfizer Investigational Site
Beijing, China, 100083
Pfizer Investigational Site
Beijing, China, 100088
Pfizer Investigational Site
Guangzhou, China, 510370
Pfizer Investigational Site
Nanjing, China, 210029
Pfizer Investigational Site
Shanghai, China, 200030
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00645372     History of Changes
Other Study ID Numbers: A1281115
Study First Received: March 24, 2008
Last Updated: April 21, 2015

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on May 25, 2017